Head of Business Disruption, Commercial IT & Digital Team, #CID. I love Stranger Things, Science4Berlin, STEM4Health, Hackathons, Biotech, Digital Health, Startups, Web3, Networking For Health, Science, Technology, Pharma, Exobiology, Space, Science Fiction, Germany, Cuba. https://www.linkedin.com/in/yeysus/ https://twitter.com/yeysus yeysus.eth/.tez/.near POAPs collections: Bayer: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/1 Bayer Haemophilia: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/24 Bayer R&D DS&AI: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/25 Bayer R&D DS&AI Posters Madrid: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/26 Bayer Hellas / Greece: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/27 Bayer Product Supply: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/28 Bayer Berlin: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/29 Bayer IT: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/30 Bayer R&D: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/31 Bayer Communities: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/32 Bayer Medical Affairs: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/33 Art by Lena Schermer.

With the aim of protecting more and more Greek patients, a new product in Cardiovascular Medicine is launched. KERENDIA is now available for patients with CKD & Type 2 Diabetes. Welcome to Bayer Hellas internal Kerendia launch event, focusing on educating & preparing the Sales Team for a successful product promotion in the Greek market. In this event, you familiarized yourselves with the promotional materials & the role plays. This is the first POAP related to a pharmaceutical product. If you received this POAP, you are a True Pioneer in the Web3 space. Bayer is proudly promoting innovative practices. https://www.bayer.com/en/poap-tc

What ever you do, do it with passion or et least with style! We in Medical Devices and eHealth stand for life changing combinations of medical devices together with our drugs. I´m proudly presenting the eHealth & Medical Software Solution team. Our joint vision is that every patient should get access to break trough eHealth solutions. Come and visit us - go/MDeH - or connect with me via Linkedin. Always keen to chat about "AI applied in med tech", "data mech in clinical practice", "if compliance and agility can coexist" & "how to get form a research hypothesis or concept to a data product"

Nice to meet you!

My name is Pinky Damani, I'm with Bayer for 14yrs, originally from Mumbai, India, but settled in NJ, USA. I love to play cricket and badminton. Married, 2 children. Currently, working on Spectrum DMW platform with CDSA, Accenture and Oracle, part of Data Transformation and Ingestion Team, I'm very excited and happy to be part of DSA&I. Looking forward to our connect!

Given the considerable amount of data that is collected throughout clinical trials, it can be asked if this data can be used to improve our understanding of the trial, regardless of outcome. The radiomics pilot seeks to provide a toolkit that is capable of analyzing the different modalities of information found in clinical trials (genome, gene expression, biomarker, clinical information, and imaging information) to derive insights into why a patient may be responding, or why a clinical trial was unsuccessful. The current efforts have focused on clinical trials in oncology, while collaborating with the RED-ONC function. Overall, the project is in its pilot state, and demonstrating a proof of concept, while documenting many challenges and learnings with the development of such a toolkit. Potential directions that could expand this toolbox include deriving the factors that best predict why a patient would stay in a clinical trial, and providing assistance with patient selection of clinical trials. Other potential directions involve suggesting why a particular trial may have been unsuccessful and providing that information back to the drug development team.